

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

**(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS;**  
**(2) CHANGE IN THE COMPOSITION OF THE INDEPENDENT  
SPECIAL COMMITTEE;**  
**(3) DELAY IN PUBLICATION OF THE 2024 INTERIM RESULTS AND  
DESPATCH OF THE 2024 INTERIM REPORT;**  
**AND**  
**(4) CONTINUED SUSPENSION OF TRADING**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2)(a) and Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated March 28, 2024 in relation to the suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on March 28, 2024; (ii) the announcement of the Company dated March 28, 2024 in relation to, among others, the delay in publication of the 2023 Annual Results; (iii) the announcement of the Company dated April 8, 2024 in relation to, among others, the establishment of the Independent Special Committee; (iv) the announcement of the Company dated May 28, 2024 on the Resumption Guidance from the Stock Exchange; (v) the announcement of the Company dated June 28, 2024 in relation to the first quarterly update on resumption progress; (vi) the announcement of the Company dated September 9, 2024 in relation to the resignation of the Company’s auditor; (vii) the announcement of the Company dated September 27, 2024 in relation to the appointment of a new auditor of the Company; and (viii) the announcement of the Company dated September 27, 2024 in relation to, among others, the change in composition of the Independent Special Committee (collectively, the “**Announcements**”).

Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the Announcements.

The Board wishes to provide an update to the Shareholders and potential investors of the Company on the development of its business operations and financial position, as well as on its resumption progress.

## **UPDATE ON BUSINESS OPERATIONS AND FINANCIAL POSITION**

The Company is a commercial stage biotech company principally engaged in developing and commercializing innovative cancer screening products to address significant unmet medical needs in the cancer screening industry in China.

As at the date of this announcement, the Group is carrying on its business operations as usual in all material respects notwithstanding the suspension of trading in the Company's shares.

The Company will continuously assess the impact of the trading suspension on the business operations and financial position of the Group, take appropriate measures and make further announcement(s) as and when appropriate.

## **UPDATE ON PROGRESS OF RESUMPTION**

Reference is made to the announcement of the Company dated May 28, 2024 on the Resumption Guidance from the Stock Exchange and the announcement of the Company dated June 28, 2024 in relation to the first quarterly update on resumption progress.

Set out below are the Resumption Guidance and a further update on the progress of resumption.

### **Resumption Guidance**

- (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications

### **Update on Resumption Progress**

As at the date of this announcement, the Company, with the Independent Special Committee having overall oversight on the Investigation, has been proactively assisting the Investigator to advance and complete the Investigation. Given the Investigation remains ongoing, additional time is required for the 2023 Annual Results to be finalized, including but not limited to assessing any financial and other potential impact of the Audit Identified Issues on the 2023 Annual Results.

As disclosed in the announcement of the Company dated September 9, 2024, DTT has resigned as auditor of the Company with effect from September 9, 2024. As disclosed in the announcement of the Company dated September 27, 2024, the Board has appointed Zhonghui Anda as auditor of the Company with effect from September 27, 2024 to fill the casual vacancy arising from the resignation of DTT.

As at the date of this announcement, the audit work for the year ended December 31, 2023 is yet to be resumed. Accordingly, the publication of the 2024 Interim Results (as defined below) has also been delayed.

The Company will announce and inform its Shareholders of the expected date of publication of the 2023 Annual Results and the 2024 Interim Results as and when appropriate.

## Resumption Guidance

- (ii) conduct an appropriate independent forensic investigation into the audit issues (including (a) the Audit Identified Issues; (b) the allegations contained in two short-selling reports against the Group published in 2023; and (c) additional issues raised by the Auditor in relation to the Audit Identified Issues), announce the findings, assess the impact and take appropriate remedial actions
  
- (iii) demonstrate that there is no reasonable regulatory concern about management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence
  
- (iv) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to comply with the Listing Rules
  
- (v) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules

## Update on Resumption Progress

As at the date of this announcement, the Investigation remains ongoing and the Company, with the Independent Special Committee having overall oversight on the Investigation, has been proactively assisting the Investigator to advance and complete the Investigation and maintaining active dialogues with all relevant parties of the Investigation to resolve the audit issues.

The Company will announce the relevant findings of the Investigation as and when appropriate in accordance with the requirements under the Listing Rules upon completion of the Investigation or any major stage(s) thereof, and will, if necessary, take appropriate remedial actions.

The Company will take appropriate actions and measures as soon as practicable upon completion of the Investigation to ensure that there does not exist reasonable regulatory concerns, if any, about the management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations.

As at the date of this announcement, the Company has appointed Forvis Mazars Risk Advisory Services Limited (the "**IC Consultant**"), an external and independent consultant with appropriate experience and credentials, to conduct the IC Review.

The Company will announce the key findings of the IC Review as and when appropriate in accordance with the requirements under the Listing Rules.

Since the suspension of trading in the Company's shares on March 28, 2024 and up to the date of this announcement, the business operations of the Group have continued as usual in all material respects. The Company's compliance with Rule 13.24 of the Listing Rules would be assessed with the publication of the 2023 Annual Results and the 2024 Interim Results.

## Resumption Guidance

- (vi) inform the market of all material information for the Shareholders and investors to appraise the Company's position

## Update on Resumption Progress

Since the suspension of trading in the Company's shares on March 28, 2024, the Company has kept its Shareholders and potential investors informed of all material information, including, among others, the audit progress, the Investigation progress, the IC Review progress and the Resumption Guidance.

The Company will continue to keep its Shareholders and potential investors informed of any relevant material development by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules.

The Company has been working and will continue to work closely with all relevant parties towards the resumption of trading in its shares; and will publish further announcement(s) and quarterly updates to keep its Shareholders and potential investors informed of the latest resumption progress and other update and development of the Company as and when appropriate and in accordance with the Listing Rules.

## CHANGE IN THE COMPOSITION OF THE INDEPENDENT SPECIAL COMMITTEE

As announced by the Company on September 27, 2024, following the resignation of Prof. Hong Wu and the appointment of Ms. Jiangnan Kong as an independent non-executive Director, Ms. Jiangnan Kong has been appointed as a member of the Independent Special Committee with effect from October 1, 2024 in the place of Prof. Hong Wu who will cease to be such upon her resignation as an independent non-executive Director. As a result, the Independent Special Committee will be composed of five independent non-executive Directors, namely Mr. Lau Ngai Kee Ricky as the chairperson, and Mr. Danke Yu, Dr. Donald Kwok Tung Li, Ms. Ng Weng Sin and Ms. Jiangnan Kong as members as from October 1, 2024.

## DELAY IN PUBLICATION OF THE 2024 INTERIM RESULTS AND DESPATCH OF THE 2024 INTERIM REPORT

As at the date of this announcement, the audit work for the year ended December 31, 2023 is yet to be resumed. Accordingly, the publication of the interim results (the "**2024 Interim Results**") for the six months ended June 30, 2024 and the despatch of the interim report (the "**2024 Interim Report**") for such period have also been delayed.

Pursuant to Rules 13.49(6) and 13.48(1) of the Listing Rules, the Company is required to publish (i) the 2024 Interim Results on a date not later than two months after June 30, 2024, i.e. on or before August 31, 2024, and (ii) the 2024 Interim Report not later than three months after June 30, 2024, i.e. on or before September 30, 2024. In light of the aforementioned circumstances, the delay in the Company's publication of the 2024 Interim Results and the despatch of the 2024 Interim Report constitutes non-compliance of Rules 13.49(6) and 13.48(1) of the Listing Rules, respectively.

The Company will publish further announcement(s) to inform the Shareholders of the progress of the publication of the 2024 Interim Results and the despatch of the 2024 Interim Report as and when appropriate.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended pending fulfilment of the Resumption Guidance.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, September 27, 2024

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU, Dr. Donald Kwok Tung LI, Mr. LAU Ngai Kee Ricky and Ms. NG Weng Sin as independent non-executive Directors.*